Total Payments
$21,105
2024 Payments
$13.18
Companies
8
Transactions
26
Payment Breakdown by Category
Research$9,150 (43.4%)
Consulting$7,250 (34.4%)
Other$2,399 (11.4%)
Travel$2,145 (10.2%)
Food & Beverage$161.55 (0.8%)
Payments by Nature
| Nature of Payment | Amount | Transactions | Share |
|---|---|---|---|
| Unspecified | $9,150 | 1 | 43.4% |
| Consulting Fee | $7,250 | 3 | 34.4% |
| Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | $2,399 | 1 | 11.4% |
| Travel and Lodging | $2,145 | 15 | 10.2% |
| Food and Beverage | $161.55 | 6 | 0.8% |
Payments by Type
General
$11,955
25 transactions
Research
$9,150
1 transactions
Top Paying Companies
| Company | Total | Records | Latest Year |
|---|---|---|---|
| Celgene Corporation | $9,150 | 1 | $0 (2018) |
| Novartis Pharmaceuticals Corporation | $6,301 | 3 | $0 (2018) |
| Sun Pharmaceutical Industries Inc. | $2,399 | 1 | $0 (2019) |
| E.R. Squibb & Sons, L.L.C. | $1,371 | 11 | $0 (2018) |
| Boehringer Ingelheim Pharma GmbH & Co.KG | $1,000 | 1 | $0 (2017) |
| Merck Sharp & Dohme Corporation | $589.98 | 4 | $0 (2018) |
| AstraZeneca UK Limited | $281.26 | 4 | $0 (2018) |
| Stryker Corporation | $13.18 | 1 | $0 (2024) |
Payment History by Year
| Year | Amount | Transactions | Top Company |
|---|---|---|---|
| 2024 | $13.18 | 1 | Stryker Corporation ($13.18) |
| 2019 | $2,399 | 1 | Sun Pharmaceutical Industries Inc. ($2,399) |
| 2018 | $14,936 | 19 | Celgene Corporation ($9,150) |
| 2017 | $3,757 | 5 | Novartis Pharmaceuticals Corporation ($2,551) |
All Payment Transactions
26 individual payment records from CMS Open Payments — Page 1 of 2
| Date | Company | Product | Nature | Form | Amount | Type |
|---|---|---|---|---|---|---|
| 01/06/2024 | Stryker Corporation | INSIGNIA (Device) | Food and Beverage | In-kind items and services | $13.18 | General |
| Category: JOINT REPLACEMENT HIPS, KNEES | ||||||
| 05/06/2019 | Sun Pharmaceutical Industries Inc. | ODOMZO (Drug) | Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program | In-kind items and services | $2,398.64 | General |
| Category: ONCOLOGY | ||||||
| 11/13/2018 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $174.80 | General |
| 11/13/2018 | AstraZeneca UK Limited | — | Travel and Lodging | In-kind items and services | $85.00 | General |
| 11/13/2018 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $11.88 | General |
| 11/13/2018 | AstraZeneca UK Limited | — | Food and Beverage | In-kind items and services | $9.58 | General |
| 10/14/2018 | Novartis Pharmaceuticals Corporation | TAFINLAR (Drug) | Consulting Fee | Cash or cash equivalent | $3,750.00 | General |
| Category: ONCOLOGY | ||||||
| 04/24/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $117.58 | General |
| 04/22/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $106.58 | General |
| 02/06/2018 | Celgene Corporation | Pomalyst (Drug) | — | Cash or cash equivalent | $9,150.00 | Research |
| Study: CC-4047-BRN-001 - Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors • Category: Hematology / Oncology | ||||||
| 01/26/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $448.14 | General |
| 01/26/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $68.09 | General |
| 01/26/2018 | Merck Sharp & Dohme Corporation | — | Travel and Lodging | In-kind items and services | $59.09 | General |
| 01/26/2018 | Merck Sharp & Dohme Corporation | — | Food and Beverage | In-kind items and services | $14.66 | General |
| 01/22/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $213.32 | General |
| 01/22/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $170.50 | General |
| 01/20/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $142.53 | General |
| 01/20/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $115.56 | General |
| 01/20/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $96.80 | General |
| 01/19/2018 | E.R. Squibb & Sons, L.L.C. | — | Food and Beverage | Cash or cash equivalent | $61.48 | General |
| 01/16/2018 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $140.26 | General |
| 11/30/2017 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $103.97 | General |
| 11/29/2017 | E.R. Squibb & Sons, L.L.C. | — | Travel and Lodging | Cash or cash equivalent | $102.64 | General |
| 10/12/2017 | Novartis Pharmaceuticals Corporation | PDR001 (Drug) | Consulting Fee | Cash or cash equivalent | $2,500.00 | General |
| 10/12/2017 | Novartis Pharmaceuticals Corporation | PDR001 (Drug) | Food and Beverage | In-kind items and services | $50.77 | General |
Research Studies & Clinical Trials
| Study Name | Company | Amount | Records |
|---|---|---|---|
| CC-4047-BRN-001 - Phase 2 clinical study of pomalidomide (CC-4047) monotherapy for children and young adults with recurrent or progressive primary brain tumors | Celgene Corporation | $9,150 | 1 |
About Mark Kieran, MD PHD
Mark Kieran, MD PHD is a Pediatric Hematology-Oncology healthcare provider based in Boston, Massachusetts. This provider has been registered with the National Plan and Provider Enumeration System (NPPES) since 04/03/2006. The National Provider Identifier (NPI) number assigned to this provider is 1790747236.
According to the Centers for Medicare & Medicaid Services (CMS) Open Payments database, Mark Kieran, MD PHD has received a total of $21,105 in payments from pharmaceutical and medical device companies, with $13.18 received in 2024. These payments were reported across 26 transactions from 8 companies. The most common payment nature is "" ($9,150).
Ad
Practice Information
- Specialty Pediatric Hematology-Oncology
- Location Boston, MA
- Active Since 04/03/2006
- Last Updated 08/14/2007
- Taxonomy Code 2080P0207X
- Entity Type Individual
- NPI Number 1790747236
Products in Payments
- Pomalyst (Drug) $9,150
- TAFINLAR (Drug) $3,750
- PDR001 (Drug) $2,551
- ODOMZO (Drug) $2,399
- INSIGNIA (Device) $13.18
Explore
Data Sources
Provider data from NPPES. Payment data from CMS Open Payments. Medicare data from CMS Medicare Provider Utilization. All data is public and updated periodically.
Pediatric Hematology-Oncology Doctors in Boston
Mr. Alan Dandrea, Md, MD
Pediatric Hematology-Oncology — Payments: $826,972
Pediatric Hematology-Oncology $826,972
Dr. Leslie Kean, Md/Phd, MD/PHD
Pediatric Hematology-Oncology — Payments: $326,453
Pediatric Hematology-Oncology $326,453
Todd Golub, M.d, M.D
Pediatric Hematology-Oncology — Payments: $247,953
Pediatric Hematology-Oncology $247,953
Dr. Stacy Croteau, Md, MD
Pediatric Hematology-Oncology — Payments: $219,942
Pediatric Hematology-Oncology $219,942
Matthew Heeney, Md, MD
Pediatric Hematology-Oncology — Payments: $201,707
Pediatric Hematology-Oncology $201,707
Christine Duncan, M.d, M.D
Pediatric Hematology-Oncology — Payments: $74,023
Pediatric Hematology-Oncology $74,023